MedPath

Evaluation of medical benefits and positive effects of the certified medical product PINK! Coach in a multi-centre, randomized controlled clinical study with breast cancer patients

Phase 4
Conditions
mamma carcinoma
C50
Malignant neoplasm of breast
Registration Number
DRKS00028699
Lead Sponsor
PINK gegen Brustkrebs GmbH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
434
Inclusion Criteria

age > 18 years

German speaking

Histologically proven breast cancer (all stages, TNM classifications, therapies)

Diagnosis of the initial disease, recurrence, metastasis within the last 6 months

In initial therapy (at least 6 weeks left at the time of recruitment) or discharge for aftercare at the time of recruitment

owning a smartphone

willingness to use PINK! Coach regularly

existence of an e-mail address

Exclusion Criteria

Estimated survival < 3 months

Use of another app to accompany cancer therapy or aftercare

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PHQ-9 sum score to the following points of time:<br>- Baseline (zum Rekrutierungszeitpunkt)<br>- T1 (after 4 weeks)<br>- T2 (after 8 weeks)<br>- T3 (after 12 weeks)<br>- T4 (longtime followup after 6 months)<br>- T5 (longtime followup after12 months)
Secondary Outcome Measures
NameTimeMethod
health-related quality of life, physical activity, resilience, fatigue:<br>- Baseline (at the time of recruitment)<br>- T1 (after 4 weeks)<br>- T2 (after 8 weeks)<br>- T3 (after 12 weeks)<br>- T4 (longtime followup after 6 months)<br>- T5 (longtime followup after 12 months)<br><br>health literacy:<br>- Baseline (at the time of recruitment)<br>- T3 (after 12 weeks)<br> <br>BMI:<br>- Baseline (at the time of recruitment)<br>- T2 (after 8 weeks)<br>- T3 (after 12 weeks)<br>- T4 (longtime followup after 6 months)<br>- T5 (longtime followup after 12 months)<br><br>economic endpoints<br>- Baseline (at the time of recruitment)<br>- T3 (after 12 weeks)<br>- T5 (longtime followup after 12 months)
© Copyright 2025. All Rights Reserved by MedPath